Skip to main content
Theravance Biopharma, Inc. logo

Theravance Biopharma, Inc. — Investor Relations & Filings

Ticker · TBPH ISIN · KYG8807B1068 LEI · 5493007VTSXP4Z6MIW52 US Manufacturing
Filings indexed 1,058 across all filing types
Latest filing 2026-05-07 Interim / Quarterly Rep…
Country KY Cayman Islands
Listing US TBPH

About Theravance Biopharma, Inc.

https://www.theravance.com/

Theravance Biopharma, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of medicines. The company aims to transform the treatment of specialty respiratory and neurologic diseases, with a research focus on inflammation and immunology. Its key commercial product, YUPELRI® (revefenacin), is an internally discovered inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Theravance Biopharma leverages its research capabilities to advance a pipeline of small-molecule drug candidates designed to address significant patient needs.

Recent filings

Filing Released Lang Actions
10-Q - Theravance Biopharma, Inc. (0001583107) (Filer)
Interim / Quarterly Report
2026-05-07 English
8-K - Theravance Biopharma, Inc. (0001583107) (Filer)
Regulatory Filings
2026-05-07 English
10-K - Theravance Biopharma, Inc. (0001583107) (Filer)
Annual Report FY 2025
2026-03-23 English
8-K - Theravance Biopharma, Inc. (0001583107) (Filer)
Regulatory Filings
2026-03-19 English
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
Director's Dealing
2026-03-18 English
8-K - THERAVANCE BIOPHARMA, INC. (0001583107) (Filer)
Regulatory Filings
2026-03-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.